Michael Lerman*
Cancer-Causing Genes Section, Laboratory of Immunobiology, National Cancer Institute, Frederick, Maryland, United States of America
*Corresponding author: Lerman M, Cancer-Causing Genes Section, Laboratory of Immunobiology, National Cancer Institute, Frederick, Maryland, USA, Email: lermanmi@gmail.com
Received Date: 18 November, 2016; Accepted Date: 5 December, 2016; Published Date: 12 December, 2016
The essence of my proposal is to use two known tumor suppressor genes expressed from episomal vectors: one delivered to cancer stem cells to suppress tumor growth, the other delivered to patient’s hematopoietic stem cells to boost the immune system to attack and destroy the tumor.
This cure program applies to all forms of cancer and all patients regardless of their genetic background, gender and age. It totally departs from the prevailing dogma that requires specific therapeutics with “targeted” drugs for each type of cancer, to be tailored to each individual tumor and patient background (“personalized treatment”).